Fresenius SE & Co KGaA (FRA:FRE) Given a €51.00 Price Target at Independent Research

Independent Research set a €51.00 ($59.30) price objective on Fresenius SE & Co KGaA (FRA:FRE) in a research report sent to investors on Friday morning, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.

Several other equities research analysts also recently commented on FRE. Morgan Stanley set a €50.00 ($58.14) target price on Fresenius SE & Co KGaA and gave the company a neutral rating in a report on Wednesday, May 22nd. Berenberg Bank set a €70.95 ($82.50) target price on Fresenius SE & Co KGaA and gave the company a buy rating in a report on Tuesday. Warburg Research set a €65.00 ($75.58) target price on Fresenius SE & Co KGaA and gave the company a buy rating in a report on Friday, July 26th. JPMorgan Chase & Co. set a €57.90 ($67.33) target price on Fresenius SE & Co KGaA and gave the company a buy rating in a report on Wednesday. Finally, Nord/LB set a €58.00 ($67.44) target price on Fresenius SE & Co KGaA and gave the company a buy rating in a report on Wednesday. Nine research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock has an average rating of Buy and a consensus price target of €58.60 ($68.14).

Shares of FRA:FRE traded down €1.08 ($1.26) during mid-day trading on Friday, hitting €44.71 ($51.98). 2,771,359 shares of the company traded hands. Fresenius SE & Co KGaA has a 52-week low of €60.16 ($69.95) and a 52-week high of €80.00 ($93.02). The stock’s 50 day moving average price is €46.65.

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Read More: Diversification For Individual Investors

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.